As seen on:
As seen on:
Latest Articles
This week’s Smart Reads spotlights blue-chip REITs to watch, UOB vs OCBC, and dividend stocks for retirement as well as top AI names like Nvidia that remain worth owning at market highs.
This week’s top stock market highlights feature Mandarin Oriental’s privatisation bid, gold’s sharp pullback after hitting US$4,300 an ounce, and how an AWS outage disrupted global airline operations.
A good checklist won’t make you Warren Buffett, but it will prevent you from being consistently wrong.
3 Singapore stocks deliver dividend yields that outshine the Straits Times Index – with income potential to match.
Frasers Centrepoint Trust, Mapletree Pan Asia Commercial Trust and Digital Core REIT have posted their latest earnings — here’s what stands out for investors.
Next week’s earnings will reveal which blue-chip REITs are building momentum and which are merely treading water.
Popular
These REITs have done well this year, but can they continue to surge higher?
We track the good performance of these five blue-chip stocks to assess if they qualify as good investment candidates.
The telco has trained its sights on growing its revenue and profits under its ST28 long-term plan.
Want a retirement you can enjoy? Here’s how dividends and growth stocks can get you there.
Stocks
Growth or income — we break down which approach gives Singapore investors the edge over time.
Three under-the-radar Singapore stocks significantly beat the 2.2% STI return in November 2025, demonstrating market-beating returns.
Three major Singapore blue-chip stocks stumbled in November, forcing investors to question if they offer a discount or signal a deeper red flag.
Centurion, AIMS APAC and FLCT emerged as November 2025’s best-performing REITs, outpacing the market with resilient portfolios and steady fundamentals.
Getting Started
As we head into a new year, here are five ways you can enhance your portfolio returns.
Will technology stocks remain relevant in the brave new world?
The world faces a different kind of problem aside from the pandemic, but one that can be tackled with pharmaceuticals.
With a potential rocky and unsteady recovery post-COVID-19, here’s how you can locate stocks that will do well.